POINTS TO CONSIDER IN THE DESIGN AND SUBMISSION OF PROTOCOLS 
FOR THE USE OF RETROVIRAL MARKERS TO DISCRIMINATE IN CML 
PATIENTS RECEIVING INTENSIVE THERAPY AND AUTOLOGOUS 
TRANSPLANTATION BETWEEN RELAPSE WHICH ARISES FROM SYSTEMIC 
DISEASE REMAINING AFTER PREPARATIVE THERAPY VERSUS RELAPSE 
DUE TO RESIDUAL LEUKEMIC CELLS IN AUTOLOGOUS MARROW 
Prepared by Albert B. Deisseroth in collaboration with H 
Kantarjian, M. Talpaz, R. Champlin, R. Moen, W. French Anderson, C 
Reading, R. Wallerstein, D. Prezipiorka, S. Giralt, B. Andersson 
M. Brenner, E. Gaozza, M. Korbling, and M.L. Filaccio 
Submitted to: Human Gene Therapy Subcommittee 
Recombinant DNA Advisory Committee 
National Institutes of Health 
Bethesda, Maryland 20892 
Recombinant DNA Research, Volume 14 
[741] 
